No abstract

Pure Ca 1-x Eu x Ta(O,N) 3 were successfully synthesized in the whole range of Ca/Eu compositions by means of ammonia nitridation via a citrate precursor route. As-nitrided products with x < 0.4 were apparently orthorhombic, while those with x ≥ 0.4 crystallized in a cubic structure. The anionic composition was found to be essentially O 2 N and independent of Eu content (x). The as-nitrided EuTaO 2 N possessed a cubic perovskite-type structure, while high-temperature post-annealing led to a tetragonal EuTaO 2 N phase with better crystallinity. The re-nitridation transformed the post-annealed product into the original cubic lattice, which might be an average of the tetragonal micro domains. *Corresponding

No abstract

These results indicate that FLG mutations might be involved in the pathogenesis of WDEIA in the present case.

No abstract

No abstract

ments for recurrent tumours and new chemotherapeutic regimens are needed. Cetuximab, in combination with paclitaxel, is an approved treatment for advanced SCC of the head and neck and has the highest disease control rate. 2 Some recent reports have demonstrated that unresectable cutaneous SCCs have been successfully treated with cetuximab. Among these reports, a durable complete response using the combination therapy with cetuximab and paclitaxel was observed. 5 Taking this evidence together, there is a possibility that the combination therapy with cetuximab and paclitaxel could be useful for various kinds of SCCs other than just head and neck. This case strongly implies that the combination therapy with cetuximab and paclitaxel is also effective for cutaneous SCCs, including vulvar SCC, and therefore randomized clinical studies for SCC of the skin and mucosa would be desirable. M. MATSUZAWA T . INOZUME References 1 Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005; 41:107-27. 2 Hitt R, Irigoyen A, Cortes-Funes H et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012; 23:1016-22. 3 Tyring SK. Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obstet Gynecol 2003; 189(3 Suppl.):S17-23. 4 Alkatout I, Schubert M, Garbrecht N et al. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health 2015; 7:305-13. 5 Mecca C, Ponzetti A, Caliendo V et al. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol 2012; 22:758-61.

Fig. 1. Clinical appearance of (a) linear keratotic papules and plaques on the right leg and (b) verrucous plaque on the dorsum of the right foot. (c) Miliary, lustrous papules distributed almost consistently with hair follicles on the abdomen.